BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
News Nov 21, 2013
Galapagos announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim.
David Smith, CEO Galapagos Services, commented, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus. It is testament to the strength and depth of BioFocus’ drug discovery capabilities and expertise in this particular gene family.”
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019